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Key Points
• Zinc is required for
multimerization of mu-
tant calreticulin, which
is a requisite event for
MPL binding and
activation.
• Zinc chelators exhibit
selective toxicity
against CALR-mutant
MPN cell lines and pri-
mary MPN cells.
Calreticulin (CALR) is mutated in the majority of JAK2/MPL-unmutated myeloproliferative
neoplasms (MPNs). Mutant CALR (CALRdel52) exerts its effect by binding to the
thrombopoietin receptor MPL to cause constitutive activation of JAK-STAT signaling. In this
study, we performed an extensive mutagenesis screen of the CALR globular N-domain and
revealed 2 motifs critical for CALRdel52 oncogenic activity: (1) the glycan-binding lectin motif
and (2) the zinc-binding domain. Further analysis demonstrated that the zinc-binding
domain was essential for formation of CALRdel52 multimers, which was a co-requisite for
MPL binding. CALRdel52 variants incapable of binding zinc were unable to
homomultimerize, form CALRdel52-MPL heteromeric complexes, or stimulate JAK-STAT
signaling. Finally, treatment with zinc chelation disrupted CALRdel52-MPL complexes in
hematopoietic cells in conjunction with preferential eradication of cells expressing
CALRdel52 relative to cells expressing other MPN oncogenes. In addition, zinc chelators
exhibited a therapeutic effect in preferentially impairing growth of CALRdel52-mutant
erythroblasts relative to unmutated erythroblasts in primary cultures of MPN patients.
Together, our data implicate zinc as an essential cofactor for CALRdel52 oncogenic activity by
enabling CALRdel52 multimerization and interaction with MPL, and suggests that
perturbation of intracellular zinc levels may represent a new approach to abrogate the
oncogenic activity of CALRdel52 in the treatment of MPNs.
Introduction
Mutations in CALR, which encodes the endoplasmic reticulum–resident chaperone protein calreticulin
(CALR) are present in the majority of JAK2/MPL-unmutated myeloproliferative neoplasms (MPNs).1,2
CALR is a calcium-binding chaperone that regulates cellular proteostasis in the endoplasmic reticulum.3
Wild-type CALR is composed of 3 domains: (1) a globular N-domain that contains lectin-, polypeptide-,
and zinc-binding motifs that enable CALR chaperone activity4-6; (2) a P-domain that forms a hairpin
structure that binds to cochaperones7,8; and (3) an acidic C-terminal tail involved in calcium buffering.9
MPN-associated CALR mutations are insertion-deletion mutations that result in a 11-bp frameshift
that generates a neomorphic C-terminal tail encoded in an alternative reading frame, with the most
common mutation being a 52-bp deletion.1,2 The resulting mutant CALR protein (CALRdel52) contains
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a mutant-specific C terminus in which most of the negatively
charged amino acids of the wild-type protein is replaced with
positively charged amino acids, such as lysine and arginine.
Multiple studies have now provided direct links between CALRdel52
and thrombopoietin receptor (MPL) signaling. Expression of
CALRdel52 confers cytokine-independent growth in conjunction
with increased JAK-STAT signaling in Ba/F3 and UT7 cell lines
coexpressing MPL, but not erythropoietin (EPO) receptor or
granulocyte-macrophage colony-stimulating factor receptor.10-12
Consistent with an essentiality of MPL in mediating CALRdel52
-associated disease, CALRdel52 was unable to induce MPN-like
disease in mice lacking Mpl.13 Mechanistic studies revealed that
CALRdel52 physically associates with the extracellular domain of
MPL10-12 through its lectin motif10,14 to activate JAK-STAT signaling
and engender cytokine-independent proliferation. Moreover,
CALRdel52 has also been shown to homomultimerize, and that
this homomultimerization is a prerequisite for MPL binding and
activation.15
In this report, we undertook a comprehensive mutagenesis screen
and uncovered a new role for 3 zinc-binding histidine residues in the
CALRdel52 N-domain essential for CALRdel52 multimerization and
MPL binding and activation. Furthermore, we found that the
CALRdel52-MPL signaling complex is dependent on intracellular
zinc. We show that zinc chelators were able to disrupt CALRdel52
-MPL signaling complexes and attenuate JAK-STAT signaling
specifically in CALR-mutant cells, and exhibited selective toxicity
against CALRdel52-positive burst-forming unit erythroid (BFU-E)
colonies from MPN patients. Our data reveal several additional
insights into the molecular mechanism of action of CALRdel52 by
identifying a central role for zinc in regulating CALRdel52 multi-
merization and its impact on MPL signaling.
Materials and methods
Cell culture reagents and antibodies
The 293T cells were derived from the American Type Culture
Collection. MPL-expressing Ba/F3 (Ba/F3-MPL) were generated by
retroviral transduction with retroviruses expressing human MPL
complementary DNA. The 293T cells were maintained in Dulbec-
co’s modified Eagle medium (DMEM; Lonza), supplemented with
10% fetal calf serum (Sigma) and 1% penicillin-streptomycin-
glutamine mix (Sigma), and cultured in 37°C with 5% CO2. Ba/F3-
MPL cells were maintained in RPMI (Lonza) supplemented with
10% fetal calf serum, 1% penicillin-streptomycin-glutamine mix, and
50 ng/mL recombinant human thrombopoietin (PeproTech) in
a vented flask, and cultured in 37°C with 5% CO2. For N,N,N9,N9-
tetrakis(2-pyridinylmethyl)-1,2-ethanediamine (TPEN) treatment,
TPEN (Sigma) was resuspended in 99% ethanol at a concentration
of 20 mM and added to media at indicated concentrations for 1 to
4 hours. For clioquinol treatment, clioquinol (Sigma) was resus-
pended in dimethyl sulfoxide at a concentration of 40 mM and
added to media at indicated concentrations for 4 hours to assess
effect intracellular signaling and 48 hours to assess cell viability.
For immunoblotting, primary antibodies were obtained from the
following sources: mouse anti-FLAG-M2 (Sigma), rabbit anti-
FLAG rabbit (Sigma), rabbit-anti-V5 (Cell Signaling), rabbit anti-
CALR (clone D3E6) (Cell Signaling), rabbit anti-pSTAT5-Y694
(clone D47E7) (Cell Signaling), rabbit anti-pSTAT3-Y705 (clone
D3A7) (Cell Signaling), rabbit anti-total STAT5 (clone D2O6Y)
(Cell signaling), rabbit anti-STAT3 (clone124H6) (Cell Signaling),
mouse anti-ACTIN (clone AC35) (Sigma), and mouse anti-MPL
(clone 1.78.1) (BD Bioscience).
Alanine mutagenesis screen
Mutagenesis of iV2-LeGO-iV2-CALRdel52 plasmid DNA was
performed using Q5 Hot Start High-Fidelity Master mix (New
England Biolabs) according to the manufacturer’s protocols. The
following thermocycling setup was used: initial denaturation 98°C
for 30 seconds, 25 cycles at 98°C for 10 seconds, 50°C to 72°C
for 20 seconds, and 72°C for 4 minutes, followed by a final
extension at 72°C for 10 minutes. Kinase, ligase, and DpnI
treatment was immediately performed following the linear amplifi-
cation for 1 hour at 37°C. The kinase, ligase, and DpnI–treated
reaction was used to transform competent Escherichia coli. DNA
was isolated from individual colonies, and presence of alanine
mutant was confirmed by Sanger sequencing. To perform
functional assays for each CALR alanine variant, lentiviral super-
natants were prepared for each alanine variant by cotransfection of
the mutagenized LeGO-iV2-CALR variant with packaging plasmids
psPAX2 and pVSV.G. After 24 hours of transfection, CALR-
expressing viral supernatants were collected, filtered, and used to
infect Ba/F3-MPL cells by spin infection at 2000 rpm at 37°C for
2 hours. Cells were allowed to recover by incubation with RPMI
supplemented with 50 ng/mL recombinant human thrombopoietin
(PeproTech) for 2 days, before cytokine withdrawal. For cytokine
withdrawal, exponentially growing Ba/F3 MPL cells transduced with
lentiviruses expressing various CALR variants were washed 3 times
with phosphate-buffered saline (PBS) and seeded in triplicate at an
initial density of 2 3 105 cells/mL in RPMI-1640 medium (Lonza)
supplemented with 10% fetal bovine serum (Sigma) and 1%
penicillin/streptomycin/L-glutamine (Sigma) in the absence of cytokine.
Living cells were counted using hemocytometers by trypan blue
exclusion assay, 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium
bromide assays or by cell counting on a flow cytometer. The ability of
each alanine variant to confer cytokine-independent growth was
depicted relative to that of an unmutated LeGO-iV2-CALRdel52
control.
FLAG pulldown assays
To assess protein complex formation of heterologously expressed
proteins, coimmunoprecipitations were performed in 293T cells.
Cells were seeded at a density of 23 105 cells/mL in a 6-well plate.
For assessing binary CALRdel52-MPL complex formation, DNA-
cationic lipid mixtures were created by combining 1.25 mg of
pCMV-SPORT6-CALR variant-expressing plasmid, 1.25 mg of
pLeGO-iT2-hMPL, and 7.5 mL TransIT-LT1 transfection reagent
(Mirus) in 250 mL of media-free DMEM. For assessing ternary
CALRdel52-MPL complexes with 2 different tagged versions of
CALRdel52, 0.625 mg of each pCMV-SPORT6-CALR variant-
expressing plasmid was used and mixed with 1.25 mg of pLeGO-
iT2-hMPL and 7.5 mL TransIT-LT1 transfection reagent in 250 mL
media-free DMEM, as discussed previously. Mixtures were allowed
to sit at room temperature for 15 minutes, and then added dropwise
to 293T cells. After 24 hours, transfected 293T cells were
harvested, washed with PBS twice, and then cells were collected
and resuspended in 450 mL NP40 lysis buffer and incubated on ice
for 30 minutes. Lysates were cleared by centrifugation at 17000g
for 10 minutes at 4°C, and 10% (usually ;50 mL) was set aside as
the total lysate “input” fraction and the remainder used for pulldown
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assays. Protein G bead-antibody mixtures were generated by
initially washing 50 mL of magnetic Protein G Surebeads (BioRad
Laboratories) per sample with PBS with 0.1% Tween-20 [PBST])
3 times using a magnet. One microliter of FLAG M2 antibody
(Sigma) was diluted with PBST and added to the beads and
incubated for 15 minutes with inversion at room temperature. FLAG
M2-Protein G beads were washed with PBST and incubated with
lysate supernatants for 1 hour at room temperature and mixed by
inversion. Lysate-bead mixtures were washed 3 times by magnetic
sorting, and beads were resuspended in 100 mL of 1X SDS
Laemmli buffer and eluted by incubating the beads for 10 minutes
at 70°C. Both pulldown fractions and lysates were analyzed by
Western immunoblotting, as described in supplemental Information.
Intracellular phosphoprotein flow cytometry analysis
Ba/F3-MPL cells expressing CALR variants were cultured in RPMI
supplemented with 10% fetal bovine serum, 5% penicillin/
streptomycin, and 5% L-Glutamine for 24 hours in the absence of
cytokines. Harvested cells were transferred into flow tubes and
washed with PBS 1 1% bovine serum albumin (BSA) twice to
remove residual RPMI media. These cells were fixed and
permeabilized using Fix&Perm Kit (Nordic MUbio). Staining was
carried out in PBS 1% BSA for 1 hour at room temperature with PE
Mouse anti-Stat3 (pY705) and Alexa Fluor 647 anti-Stat5 (pY694)
(BD Biosciences). Cells were washed with PBS with 1% BSA and
samples were analyzed using a CytoFLEX Flow Cytometer (Beck-
man Coulter Life Sciences). Data analysis was performed with
CytExpert V2.2.
Confocal microscopy and FRET analysis
The 293T cells were seeded into 35mm, high, m-Dish with an ibidi
polymer coverslip bottom and were incubated overnight at 37°C.
Transient co-transfection of pSport6-Cherry-CALR variant-FLAG
with MSCV-GFP-MPL in a 1:1 ratio was performed using TransIT-
LT1 (Mirus). Following 24 hours post-transfection, cells were gently
washed and resuspended with phenol red-free DMEM media,
and cells were imaged using Zeiss LSM 880 inverted confocal
microscopy. Fluorescence resonance energy transfer (FRET) was
measured by exciting sample at donor excitation of 488 nm and
measuring the acceptor excitation absorbance at 610 nm. FRET
intensity was calculated by using sensitized emission.
TPEN treatment of clonal erythroblasts from
MPN patients
MPN patients were diagnosed according to the British Committee
for Standards in Hematology guidelines.16 UK patient samples were
obtained under local ethics approval (Cambridge and Eastern
Region Ethics Committee) or as part of the UK Medical Research
Council PT-1 trial.17 Written informed consent was obtained from
all patients in accordance with the Declaration of Helsinki. For
local Cambridge patients, samples were taken at the time of the
initial patient visit on referral to the specialist MPN clinic at the
Addenbrooke’s Hospital in Cambridge, United Kingdom. Venous
blood samples (20 mL) were collected from each patient and
peripheral blood mononuclear cells (PBMCs) were isolated using
Lymphoprep (Axis Shield PLC) according to the manufacturer’s
protocols and plated in complete MethoCult medium (H4435;
STEMCELL Technologies) at a density of 3 3 105 cells/mL and
incubated at 37°C and 5% CO2 for 14 days. When indicated,
MethoCult was supplemented with 5 mM TPEN (Sigma). After 14
days, colonies were plucked into 20 mL PBS. For each colony,
5 mL was denatured at 95°C for 15 minutes to release cellular
DNA and subjected to polymerase chain reaction using primers to
amplify exon 9 of the CALR gene (forward primer: 59-GCA GCA
GAG AAA CAA ATG AAG G-39; reverse primer: 59-AGA GTG
GAG GAG GGG AAC AA-39). Polymerase chain reaction
conditions were an initial preheating at 94°C for 10 minutes was
followed by denaturation at 94°C for 30 seconds, annealing at
64°C for 30 seconds, and extension at 72°C for 30 seconds for
40 cycles, followed by a final extension at 72°C for 7 minutes.
Amplicons were submitted for Sanger sequencing to identify
colony genotypes.
Results
Alanine mutagenesis screen of CALRdel52 N-domain
demonstrates residues associated with lectin and
zinc-binding activity are essential for
oncogenic activity
We and others previously reported the lectin motif within the
CALRdel52 N-domain was essential for MPL binding.10,14 To resolve
other regions within the N-domain potentially necessary for
oncogenic activity, we undertook an alanine mutagenesis screen
of the entire N-domain by screening for the ability of single-residue
loss-of-function variants to engender cytokine-independence in
MPL-expressing Ba/F3 (Ba/F3-MPL) cells. We observed that the
majority of the 177 single-residue alanine mutants did not affect
CALRdel52 activity, with only 9 residues abrogating cytokine in-
dependence by a factor greater than 1 standard deviation from the
mean when mutated (Figure 1A). Specifically, CALRdel52 harboring
C105A, K111A, G133A, or D135A mutations exhibited total
abrogation of cytokine independence (Figure 1B, left), decreased
STAT3/5 phosphorylation as assessed by intracellular flow cytometry
(Figure 1C) and immunoblotting (Figure 1D), and an inability to bind
MPL in FLAG-pulldown assays (Figure 1E). These residues have
previously been implicated in the lectin activity of wild-type CALR,18
and D135 specifically has previously been shown by us and others
to be required for CALRdel52 oncogenic activity.10,14 In addition,
CALRdel52 harboring Y109A and Y128A mutations only exhibited
partial loss of cytokine independence (Figure 1B, right) and exhibited
no effect on STAT3/5 phosphorylation or MPL binding (Figure 1C-E),
despite these residues also having been implicated in wild-type CALR
lectin activity. Of note, other residues thought to be essential for CALR
lectin motif such as M131 and I147 did not exhibit any effect in our
screen (Figure 1A). Overall, these data accord with previous findings
that the lectin motif of CALRdel52 is essential for oncogenic activity,
but suggest that different residues within the lectin motif of CALRdel52
may have differential effects in facilitating its oncogenic activity.
Next, we examined the other residues identified in our screen that
have not previously been associated with glycan binding. We
observed that CALRdel52 harboring H99A, H145A, and H170A
mutations (1His) exhibited partial abrogation of cytokine indepen-
dence (Figure 1A and Figure 2A, left). Because these residues have
been reported to need to function in a concerted manner to
coordinate zinc,19 we tested whether combined loss of multiple
residues would have more deleterious consequences on CALRdel52
activity. Indeed, we observed that loss of any 2 or all 3 histidine
residues in combination (2His and 3His, respectively) led to




 http://ashpublications.org/bloodadvances/article-pdf/5/7/1922/1804418/advancesadv2020002402.pdf by guest on 07 April 2021
significant impairment of cytokine-independent growth (Figure 2A,
middle and right), in conjunction with decreased pSTAT3/5
phosphorylation (Figure 2B-C).
To ensure that these results are specific to these individual zinc-
binding histidine residues and not from nonspecific effect on
CALRdel52 stability, we also tested the effects of CALRdel52 in which
H42, which is predicted to lie on the opposite face of CALRdel52
and is not thought to function in concert with H99, H145, or H170
to bind zinc,18 is mutated. We observed that CALRdel52 variants
harboring H42A mutations or of H42A in combination with H99,
H145, or H170 were unaffected in their ability to confer cytokine-
independent growth (supplemental Figure 1A) and retained the
capacity to promote STAT3/5 phosphorylation (supplemental
Figure 1B-C).
Finally, we also tested whether histidine-deficient CALRdel52 variants
could physically associate with MPL by co-immunoprecipitation
assays. We observed that 1His-CALRdel52 variants retained the
ability to bind to MPL in FLAG pulldowns, but not 2His or 3His
variants (Figure 2D). We also tested the ability of histidine-
deficient CALRdel52 variants to colocalize intracellularly with MPL
using FRET. To achieve this, histidine-deficient CALRdel52 variants
were generated fused to an mCherry fluorescent marker and
introduced to 293T cells in conjunction with an MPL-GFP fusion
protein; colocalization was measured by quantification of energy
transfer of the mCherry donor to the GFP acceptor. Significant
FRET was observed for mCherry-tagged CALRdel52 and MPL-
GFP indicative of intracellular colocalization, whereas minimal
FRET was observed for mCherry-tagged wild-type CALR and
MPL-GFP (supplemental Figure 2). Analysis of 100 cells for each
histidine-deficient CALRdel52 variants indicated that MPL colocal-
ized strongly with 1His-CALRdel52 variants, but not with 2His and
3His variants (Figure 2E).
Cumulatively, functional analysis of single-residue CALRdel52








































































































































































Figure 1. The lectin-dependent function of CALR
del52
is required for cytokine-independent growth. (A) Alanine mutagenesis screen to assess ability of 177
CALRdel52 single-residue mutants to confer cytokine-independent growth of Ba/F3-MPL cells, as depicted on y-axis by number of cell divisions following 3 days. The mutagen-
ized residue is represented on the x-axis. The 9 residues that are .1 standard deviation away from mean are indicated with arrows. Putative lectin residues are denoted in
brown; putative zinc-binding residues are denoted in red. (B) Growth curves of Ba/F3-MPL cells expressing wild-type CALR, CALRdel52, or lectin motif variants demonstrate
total (left) or partial (right) impairment of cytokine-independent growth. Testing for statistical significance was performed using a Student t test (*P , .05; **P , .01; ***P ,
.001). (C) Intracellular phosphorylation flow cytometry and (D) Western immunoblotting demonstrate diminished Stat3 and Stat5 phosphorylation in Ba/F3-MPL cells express-
ing nontransforming CALRdel52 lectin variants. Numbers in red indicate ratio of mean fluorescence intensity for each sample relative to isotype control. The data are representa-
tive of 2 independent experiments. (E) Immunoblotting of FLAG-immunoprecipitated proteins from 293T cells cotransfected with FLAG-tagged CALRdel52 lectin variants and
MPL-expressing vector demonstrates impaired MPL binding capacity by nontransforming lectin variants.





















































































































































































































Figure 2. A triad of zinc-binding histidine residues in CALRdel52 are required for cytokine-independent growth. (A) Growth curves in Ba/F3-MPL cells expressing
histidine-deficient CALRdel52 variants harboring loss of either 1 histidine (1His), 2 histidines (2His), or 3 histidines (3His). Immunoblotting (B) and intracellular phospho-flow
cytometry (C) demonstrate diminished Stat3 and Stat5 phosphorylation in of Ba/F3-MPL cells expressing 2His- and 3His-CALRdel52 variants. Numbers in red indicate ratio of
mean fluorescence intensity for each sample relative to isotype control. The data are representative of 2 independent experiments. (D) Immunoblotting of FLAG-
immunoprecipitated proteins from 293T cells cotransfected with histidine-deficient FLAG- CALRdel52 variants and MPL-expressing vectors demonstrates abolished MPL bind-
ing capacity by 2His- and 3His-CALRdel52 variants. (E) Single-cell data for FRET intensity. FRET fluorescence units depict energy transfer between mCherry-tagged histidine-
deficient CALRdel52 protein and MPL-GFP in arbitrary fluorescence units for a single cell. For each experimental condition, 100 cells were analyzed.
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are important for mediating the ability of CALRdel52 to bind and
activate MPL and confer cytokine independence: (1) residues
associated with lectin motif and (2) histidine residues putatively
associated with zinc binding.
Histidine-mutated CALRdel52 is incapable
of homomultimerization
A recent study detected CALRdel52 homomultimerization by
pulldown of distinct CALRdel52 molecules tagged with 2 different
epitopes.15 We used the same strategy to test the multimerization
capacity of lectin-deficient or histidine-mutated CALRdel52. We
confirmed these findings by assessing the ability of FLAG-tagged
CALRdel52 (bait) to complex and co-immunoprecipitate with a V5-
tagged CALRdel52 species (prey) in 293T cells (Figure 3A), and
demonstrated that CALRdel52 is capable of interacting with
CALRdel52 but exhibited impaired ability to bind to wild-type CALR
(Figure 3B). Using this experimental setup, we next tested the
multimerization capacity of lectin-deficient or histidine-mutated
CALRdel52. We observed that the lectin-deficient CALRdel52 and
all 3 1His-CALRdel52 variants retained multimerization capacity
equivalent to that of CALRdel52 (Figure 3B-C). In contrast, we
observed that the 2His- and 3His-CALRdel52 were impaired in their
capacity to multimerize with CALRdel52 (Figure 3C). To ensure that
these activities were not an artifact of assessing binding with
unmutated CALRdel52, we also tested the ability of lectin-deficient
or histidine-mutated CALRdel52 to multimerize with another lectin-
deficient or histidine-mutated CALRdel52, respectively, and form
homomultimers. Consistent with our earlier data, we observed
that the lectin-deficient CALRdel52-D135A retained the ability
to homomultimerize with another CALRdel52-D135A, but the
histidine-mutated 3His-CALRdel52 was not able to homomultimerize
with another 3His-CALRdel52 (Figure 3D). Our data therefore
accord with previous reports that CALRdel52 forms homomultimers,
but our data show that homomultimerization is necessary but not
sufficient for MPL binding.
Zinc is essential for CALRdel52-MPL complex
formation and downstream signaling
H99, H145, and H170 have previously been implicated in zinc-
binding capacity of wild-type CALR.19 Therefore, to confirm that loss
of zinc coordination underpinned the loss of oncogenic capacity of
2His- and 3His-CALRdel52, we performed affinity chromatography
using a zinc resin and found that CALRdel52 and 1His-CALRdel52
could readily be retained in the zinc-bound fraction, but that wild-type
CALR, 2His-, and 3His-CALRdel52 exhibited diminished zinc binding
(Figure 3E). That wild-type CALR did not bind to the zinc resin is
somewhat surprising because wild-type CALR has previously
been shown to bind zinc.10 This may suggest that the assay used
in our study was not sufficiently sensitive to detect the wild-type
CALR-zinc interaction, and that there may be differences in the
avidity of wild-type and mutant CALR monomers to zinc and/or
that CALRdel52 (but not wild-type CALR) forms multimers or
aggregates when bound to zinc, resulting in greater recovery
upon elution. Cumulatively, these data are consistent with the
finding that 2His- and 3His-CALRdel52 exhibit loss of zinc
binding.
These data therefore suggested that binding to zinc could be
required for CALRdel52 multimerization and MPL binding. To test
this, FLAG- and V5-tagged CALRdel52 and MPL were expressed in
293T cells, treated with agents that modulate zinc levels
and FLAG pulldown was performed to assess the extent of
CALRdel52 multimerization and MPL binding in heteromeric
complexes (Figure 3F). To modulate zinc levels, TPEN was used
as a membrane-permeable ion chelator with a high affinity for
zinc.20 Treatment with TPEN led to decreased CALRdel52
multimerization and impaired MPL binding (Figure 3G), suggest-
ing that zinc is required for CALRdel52 to multimerize and interact
with MPL.
These data would predict that zinc chelation could abolish cytokine
independence and JAK-STAT signaling specifically in CALRdel52
-expressing hematopoietic cells but potentially not in cells
expressing other MPN oncogenes. We therefore tested the effect
of TPEN on cytokine-independent growth of CALRdel52-expressing
Ba/F3-MPL cells (Ba/F3-MPL-CALRdel52), and observed that TPEN
treatment led to increased cytotoxicity (Figure 4A) and attenuated
STAT3/5 phosphorylation (Figure 4B; supplemental Figure 3), which
were correlated with decreased interaction between CALRdel52 and
MPL (Figure 4C). Moreover, the effect on JAK-STAT signaling
was specific to CALRdel52 because Ba/F3 cells transformed with
the alternate MPN oncogene MPLW515L (Ba/F3-MPLW515L) was
less sensitive to TPEN-induced cytotoxicity and reduction of
STAT3/5 phosphorylation (Figure 4A-B; supplemental Figure 3),
despite equivalent reduction of intracellular zinc (supplemental
Figure 4A-C). Similar results were obtained using a cytokine-
dependent megakaryocytic cell line UT7 coexpressing MPL.
TPEN induced CALRdel52-specific cytotoxicity in UT7 cells
(supplemental Figure 5A), disassociation of MPL-CALRdel52
complexes (supplemental Figure 5B), and selective abrogation
of JAK-STAT signaling in CALRdel52-expressing cells (supple-
mental Figure 5C).
Next, to ensure this effect was generalizable to other zinc chelators,
we also tested whether clioquinol, which has also been reported to
have zinc-chelating activity,21 had a similar effect. As with TPEN,
treatment of cells with clioquinol also led to preferential CALRdel52
cytotoxicity in Ba/F3-MPL cells (Figure 4D) and abrogation of JAK-
STAT signaling (Figure 4E). Moreover, clioquinol could also promote
disassociation of MPL-CALRdel52 complexes in 293T cells
(Figure 4F) These data suggest that sensitivity to zinc homeosta-
sis is a feature of CALRdel52-induced MPN.
TPEN preferentially eradicates CALR-mutant primary
MPN cells
Finally, we tested the effect of zinc chelation on CALR-mutant
primary MPN cells. We initially performed tests to identify TPEN
concentrations which would affect growth of wild-type BFU-Es
grown from PBMCs in semisolid medium, and observed no impaired
growth of wild-type colonies at TPEN dosages lower than at 3 mM
(Figure 5A). Next, PBMCs from 5 CALRdel52-mutated myelofibrosis
(MF) patients (with allele burdens ranging from 20% to 73%) were
grown in semisolid medium supplemented with 2.5 mM TPEN. After
14 days, BFU-Es were plucked and genotyped for the presence of
CALR mutation by Sanger sequencing. In 4 of 5 MF patients
examined, TPEN treatment led to decreased growth of CALRdel52
-positive BFU-E colonies compared with autologous wild-type
colonies (Figure 5B), with the fraction of mutant colonies in TPEN-
treated cultures reduced to 74% compared with untreated cultures
(P5 .053) (Figure 5C). The effect of TPEN appeared to be specific
to CALR-mutant cells because no selective effect was observed on
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JAK2V617F-mutant BFU-Es in response to TPEN in 4 JAK2-mutant
MF patients examined (Figure 5D-E), and no CALRdel52 mutant-
specific eradication was observed following treatment with an
establishedMPN treatment, hydroxyurea (Figure 5F-G). Cumulatively,
these data provide a proof of principle that zinc chelation selectively
affects the growth of CALRdel52-positive patient-derived BFU-Es and






















































































































































































Figure 3. Zinc binding by CALRdel52 is required for homomultimerization and enables MPL activation. (A) Schematic depicting co-immunoprecipitation assay for
detecting FLAG-tagged and V5-tagged CALRdel52 multimers. (B) FLAG-pulldown assays demonstrating CALRdel52 lectin variants retain ability to bind to V5-CALRdel52. (C)
FLAG-pulldown assays demonstrating 2His- and 3His-CALRdel52 are compromised in ability to bind V5-CALRdel52 compared with 1His-CALRdel52. (D) FLAG-pulldown assays
of cells transfected with FLAG- and V5-tagged CALRWT (lane 1), CALRdel52 (lane 2), CALRdel52 D135A lectin variant (lane 3), or 3His-CALRdel52 variant (lane 4) demonstrat-
ing that CALRdel52 and CALRdel52 D135A are capable of homomultimerization, but not CALRWT and 3His-CALRdel52. (E) Affinity chromatography demonstrating 2His- and
3His-CALRdel52 bind less efficiently to zinc resin compared with 1His-CALRdel52. (F) Schematic depicting co-immunoprecipitation assay for detecting heteromeric complexes
comprising FLAG-tagged and V5-tagged CALRdel52 proteins and MPL. (G) FLAG-pulldown assays demonstrating zinc chelator TPEN treatment disrupts CALRdel52 multi-
merization and MPL binding in 293T cells.
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Discussion
Multiple studies have now provided evidence that CALR mutations
coopt the MPL-JAK2 signaling axis to engender an MPN phenotype
and that this is achieved by direct interaction between CALRdel52
and the MPL extracellular domain.10-12 In this report, we attempt to
provide further molecular insights into how the CALRdel52-MPL
binding event is governed. We identified a triad of zinc-binding
histidine residues within the CALRdel52 N-domain, which is required
for both CALRdel52 homomultimerization and MPL binding, and for
engendering the MPN phenotype. To our knowledge, our report is
the first demonstrating of the importance of zinc as an essential
cofactor in mediating MPN oncogenic signaling.
The precise mechanism by which zinc enables CALRdel52 multi-
merization and MPL activation remains unclear. It was somewhat
surprising that 2His- and 3His-CALRdel52 molecules were incapable
of binding to MPL despite the presence of an intact lectin motif. We
can envision 2 potential explanations for this finding. One possibility
is that zinc binding is required to ensure proper conformation of the
lectin motif, and that the absence of zinc renders the lectin motif
nonfunctional. Our data point toward a second possibility, whereby
CALRdel52 cannot bind to MPL as a monomer but rather needs to
engage MPL as a multimer, and that zinc is necessary to mediate
this multimerization. Under this scenario, binding by CALRdel52 to MPL
could require both an intact lectin motif and the capacity for zinc-
dependent homomultimerization (Figure 5H). Indeed, there is pre-
cedent for a role for ligand multimerization in cytokine signaling. For
example, EPO has been found to form high-molecular-weight species
when purified22 and EPOdimers have been shown to exhibit more than
26-fold higher biological activity than its monomeric form.23 Finally, it is
possible that these 2 possibilities are not mutually exclusive because
mutant CALR multimerization could affect the activity of the lectin
motif through an unknown mechanism to enhance its ability to bind
MPL. Atomic level resolution of the structure CALRdel52-MPL complex
will likely be required to resolve these outstanding issues.
Finally, our findings have potential therapeutic implications. Our
data show that chemical chelation of intracellular zinc by 2 different
heavy metal chelators was able to promote disassembly of the
CALRdel52-MPL complex and cause attenuation of JAK-STAT
signaling in CALR-mutant cells. Moreover, zinc chelation led to
growth inhibition of CALRdel52-positive erythroblasts from primary
MF samples. These data are, to our knowledge, the first to implicate
heavy metal homeostasis in MPN pathogenesis and have the
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Figure 4. Zinc chelation abrogates CALR
del52
-induced JAK-STAT signaling in hematopoietic cell lines. (A) Viability of BaF3-MPL cells expressing CALRdel52 or
MPLW515L following treatment with TPEN for 48 hours. Each point represents the mean of 3 independent cultures. Testing for statistical significance was performed using
a Student t test (*P , .05). (B) Immunoblotting demonstrates decreased Stat3 and Stat5 phosphorylation status following TPEN treatment of 4 hours in CALRdel52-expressing
Ba/F3-MPL cells but not in Ba/F3-MPLW515L cells. (C) FLAG-pulldown assays demonstrating zinc chelator TPEN treatment disrupts CALRdel52-MPL binding in CALRdel52
-expressing Ba/F3-MPL cells. (D) Viability of BaF3-MPL cells expressing CALRdel52 or MPLW515L following treatment with clioquinol (CQ) for 48 hours. Cell viability was
quantified by 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide assays. Each point represents the mean of 3 independent cultures. The data are representative of at
least 2 independent experiments. Testing for statistical significance was performed using Student t test (*P , .05). (E) Immunoblotting demonstrates decreased Stat3 and
Stat5 phosphorylation status following CQ treatment of 4 hours in CALRdel52-expressing Ba/F3-MPL cells but not in Ba/F3-MPLW515L cells. (F) Immunoblotting of FLAG-
immunoprecipitated proteins in 293T cells expressing CALRdel52 and MPL demonstrates disruption of CALRdel52-MPL binding following CQ treatment of 4 hours.
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heavy metal chelators for treatment of CALR-mutated MPNs.
Moreover, these data also open up the possibility that agents that
interfere with CALRdel52 multimerization could also be an effective
therapeutic strategy for impairing CALRdel52 oncogenic activity.
In conclusion, our data provide several novel insights into the
molecular mechanism by which CALRdel52 interacts with MPL to
induce MPN. Specifically, we (1) uncover a triad of zinc-binding
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Normal CALRdel52 Lectin-deficient Histidine-deficient TPEN treatment
Figure 5. Zinc chelation exhibits selective cytotoxicity against CALR-mutant cells from MPN patients. (A) BFU-E colony counts of PBMCs from healthy volunteers
grown in methylcellulose in the presence of 0 to 5 mM TPEN. (B) PBMCs from 5 myelofibrosis patients (allele burden ranging from 20% to 73%) were cultured in the
presence and absence of 2.5 mM TPEN, and BFU-Es genotyped for the presence of CALR del52 mutation after 14 days. Proportion of colonies with wild-type CALR (wt),
heterozygous for CALR del52 mutation (del52 het), or homozygous for CALR del52 mutation (del52 hom) cultured in the presence and absence of 2.5 mM TPEN. At least 20
colonies were genotyped for each patient. (C) Average fold change of CALR-mutant colonies (including heterozygous and homozygous colonies) for 5 MF patients examined
following TPEN treatment relative to untreated cultures, which was arbitrarily designated as 1. (D) Proportion of colonies with JAK2 (wt), heterozygous for JAK2V617F mutation
(VF het), or homozygous for JAK2V617F mutation (VF hom) cultured in the presence and absence of 2.5 mM TPEN. At least 20 colonies were genotyped for each patient. (E)
Average fold change of JAK2-mutant colonies (including heterozygous and homozygous colonies) for 4 MF patients examined following TPEN treatment relative to untreated
cultures, which was arbitrarily designated as 1. (F) Proportion of colonies with CALR (wt), heterozygous for CALR del52 mutation (del52 het), or homozygous for CALR del52
mutation (del52 hom) cultured in the presence and absence of 2 mM hydroxyurea (HU). At least 15 colonies were genotyped for each patient. (G) Average fold change of
CALR-mutant colonies (including heterozygous and homozygous colonies) for 3 MF patients examined following HU treatment relative to untreated cultures, which was arbi-
trarily designated as 1. (H) Model depicting interplay between zinc, CALRdel52 multimerization and MPL activation. (C-G) Testing for statistical significance was performed using
Student t test (*P , .05).
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provide evidence that zinc-dependent homomultimerization of
CALRdel52 underlies its ability to bind MPL; and (3) determine that
reduction of intracellular zinc abrogates the oncogenic activity of
CALRdel52 and could represent a new therapeutic modality in the
treatment of CALR-mutant MPNs.
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